Cell-Culture Manufacturing Key To Boosting Flu Vaccine Supply, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Congress’ top priority in strengthening the flu vaccine supply should be funding research in cell-cultured manufacturing, FDA Acting Commissioner Crawford tells Senate committee. However, even with cell-culture technology, flu vaccine market is unlikely to regain all of its previous suppliers, he suggests.